Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Korro Bio Inc

KRRO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$13.51

▲ +10.38%

Market Cap $198.94M · Vol 39.27K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$198.94M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+41.00%

YoY

RSI (14)

52.16

Momentum

Beta

3.07

vs Market

52W High

$55.08

75.47% below

52W Low

$5.22

158.81% above

Volume

39.27K

Avg 36.43K

P/B

1.47

Price-to-book

ROE

N/A

Return on equity

Free Float

99.18%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Korro Bio Inc (KRRO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KRRO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.17%

+1.96%

+27.57%

+20.84%

YTD

+68.66%

-58.97%

-37.60%

-96.37%

Financials & Valuation

TTM · Annual

Total Revenue	$6.39M
Net Income	$-117,260,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-1,366.43%
Net Profit Margin	-1,834.48%
ROE	N/A
ROA · ROIC	-68.65% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	11.77
P/B	1.47
P/FCF	N/A
EPS Growth	+41.00%
Outstanding Shares	14.73M

Technical Indicators

50-Day SMA	$12.66
200-Day SMA	$11.28
RSI (14)	52.16
Beta	3.07
52-Week High	$55.08
52-Week Low	$5.22

Volume Today	39.27K
Avg Daily Volume (30D)	36.43K
Relative Volume	1.08x
Volatility (10D)	69.55
Volatility (30D)	61.75
Free Float	99.18%

Analyst Consensus

BUY

Current Price $13.51

Mean Target $20.00

52W Low$5.22 52W High$55.08

Current

Target

$5.22 $55.08

Current Analyst target

+48.04% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00GFMTC47

ISINUS5009461089

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.82% RVMD Revolution Medicines Inc -1.29% ONC BeOne Medicines AG -1.89% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +3.62%

Company Profile

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.